On March 6, 2023 the U.S Food and Drug Administration (FDA) approved a single-dose, prefilled autoinjector presentation of pegfilgrastim-cbqv, a biosimilar pegfilgrastim administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia. 

For more information read the Coherus Biosciences announcement. 

Posted 3/8/2023